CR

Curis

- NASDAQ:CRIS
Last Updated 2019-08-23
  • About

    Curis develops Erivedge, a capsule manufactured for the treatment of adults with skin cancer.
  • Domains

  • Locations

    • Cambridge MA
  • Total Funding (USD)

    8.0 million
  • Industries

    Real Estate, Mobile Apps, Cyber Security
  • Security

    Type: ORD
    CUSIP: 231269101
    ISIN: US2312691015

Request a demo to view additional historical data, and much more.